ERAS
Erasca, Inc.
| Exchange: | NASDAQ |
| Market Cap: | 5.535B |
| Shares Outstanding: | 118.955M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Jonathan E. Lim | |||||
| Full Time Employees: | 103 | |||||
| Address: |
| |||||
| Website: | https://www.erasca.com |
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
No earnings call materials on file for this symbol yet.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | -3,732 | 0 | -3,107 |
| EBITDA | -121,310 | -153,282 | -128,298 |
| Operating Income | -141,525 | -179,587 | -131,405 |
| Net Income | -125,042 | -161,650 | -124,546 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 395,297 | 502,526 | 396,154 |
| Total Liabilities | 78,611 | 79,027 | 70,983 |
| Total Stockholders Equity | 316,686 | 423,499 | 325,171 |
| Total Debt | 55,859 | 51,889 | 47,139 |
| Cash and Cash Equivalents | 93,075 | 67,739 | 73,805 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -101,217 | -109,417 | -95,455 |
| Capital Expenditure | -1,775 | -22,560 | -128 |
| Free Cash Flow | -102,992 | -131,977 | -95,583 |
| Net Income | -125,042 | -161,650 | -124,546 |
| Net Change in Cash | -191,142 | -25,336 | 6,066 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 299,267.200 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 299,267.200 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 299,267.200 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -112,279.344 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -112,279.344 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -112,279.344 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -0.400 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -0.400 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -0.400 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 3 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Position: ERAS demonstrates a healthy balance sheet with significant cash and cash equivalents, as well as a favorable current ratio (TTM), indicating strong liquidity to meet short-term obligations. This provides a buffer for operational stability and potential investments.
- Positive Revenue Growth: Historical income statements show consistent revenue increases over recent years, reflecting the company’s ability to expand its market presence and generate income, potentially driven by product innovation or market demand within the industry.
- Strong Operating Cash Flow: Cash flow statements indicate robust net cash provided by operating activities, suggesting efficient core business operations and the ability to sustain operations without relying heavily on external financing.
- Industry Performance Alignment: ERAS’s performance metrics (perf1w, perf1m, perf3m) align with or exceed industry averages (industry_perf1w, industry_perf1m, industry_perf3m), positioning the company competitively within its sector.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about ERAS valuation
Is Erasca, Inc. (ERAS) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Erasca, Inc. (ERAS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ERAS a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ERAS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ERAS’s P/E ratio?
You can see ERAS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ERAS?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ERAS a good long-term investment?
Whether ERAS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Trading Metrics:
| Open: | 16.65 | Previous Close: | 16.6 | |
| Day Low: | 16.29 | Day High: | 18.17 | |
| Year Low: | 1.01 | Year High: | 18.18 | |
| Price Avg 50: | 13.32 | Price Avg 200: | 5.25 | |
| Volume: | 5.27M | Average Volume: | 6.028M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeERAS full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Erasca, Inc., a clinical-stage biotech company trading under the ticker ERAS on NASDAQ. If you’re curious about investing in the biotech space, specifically in precision oncology, stick around because we’re breaking down everything from financials to recent performance and long-term potential. Let’s get started! So, first things first, let’s talk about who Erasca is and what they’re all about. Erasca is a company laser-focused…
